drugset / Trial / NCT01464320

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

NCT01464320 ↗

Phase 1 Completed 16 enrolled Abbott
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.

Timeline

Start
2011-11
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-614 Unknown 10 mg —